Neurocrine Biosciences Publishes Expert Guidelines for Glucocorticoid Dose Reduction in CAH Treatment
Neurocrine Biosciences has announced the publication of expert recommendations for reducing glucocorticoid (GC) doses in patients with classic congenital adrenal hyperplasia (CAH) who are treated with CRENESSITY (crinecerfont). These guidelines, published in The Journal of Clinical Endocrinology & Metabolism, provide structured algorithms for healthcare providers to manage GC dosing in both pediatric and adult patients. CRENESSITY, a corticotropin-releasing factor type 1 receptor antagonist, helps control excess androgen production, allowing for more physiologic GC dosing while maintaining necessary cortisol replacement. The recommendations aim to address the critical need for practical guidance as the use of CRENESSITY expands in real-world settings. 
